 Ryota Shirai
Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 288 | 1.390 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 96 | 1.010 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2024 | 214 | 0.850 |
Why?
| | Cadherins | 1 | 2024 | 205 | 0.780 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 192 | 0.760 |
Why?
| | beta Catenin | 1 | 2024 | 253 | 0.750 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 41 | 0.740 |
Why?
| | Lymphoma | 1 | 2023 | 208 | 0.730 |
Why?
| | Neuroblastoma | 1 | 2022 | 160 | 0.700 |
Why?
| | SMARCB1 Protein | 1 | 2020 | 31 | 0.650 |
Why?
| | Mosaicism | 1 | 2020 | 73 | 0.630 |
Why?
| | Rhabdoid Tumor | 1 | 2020 | 99 | 0.600 |
Why?
| | Kidney Neoplasms | 2 | 2020 | 401 | 0.580 |
Why?
| | Brain Neoplasms | 2 | 2023 | 1235 | 0.450 |
Why?
| | Bone Neoplasms | 2 | 2025 | 247 | 0.380 |
Why?
| | Germ-Line Mutation | 3 | 2023 | 172 | 0.360 |
Why?
| | Neoplasms, Second Primary | 2 | 2023 | 116 | 0.350 |
Why?
| | Pyrophosphatases | 2 | 2022 | 28 | 0.240 |
Why?
| | Liquid Biopsy | 2 | 2022 | 14 | 0.230 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1272 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.230 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2024 | 25 | 0.220 |
Why?
| | RNA-Binding Protein EWS | 1 | 2024 | 26 | 0.220 |
Why?
| | Mercaptopurine | 1 | 2022 | 16 | 0.200 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2022 | 9 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.190 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 133 | 0.190 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 346 | 0.190 |
Why?
| | Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2021 | 7 | 0.190 |
Why?
| | DNA, Neoplasm | 1 | 2022 | 164 | 0.180 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 182 | 0.180 |
Why?
| | Leukemia | 1 | 2023 | 238 | 0.170 |
Why?
| | GATA2 Transcription Factor | 1 | 2020 | 15 | 0.170 |
Why?
| | Child | 8 | 2025 | 21822 | 0.160 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 242 | 0.160 |
Why?
| | Gene Frequency | 1 | 2020 | 520 | 0.150 |
Why?
| | Myelodysplastic Syndromes | 1 | 2020 | 134 | 0.150 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2018 | 11 | 0.150 |
Why?
| | Sarcoma, Clear Cell | 1 | 2018 | 10 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 718 | 0.150 |
Why?
| | Busulfan | 1 | 2018 | 16 | 0.150 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2018 | 17 | 0.150 |
Why?
| | Gene Deletion | 1 | 2020 | 389 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2018 | 39 | 0.150 |
Why?
| | Receptors, Retinoic Acid | 1 | 2018 | 43 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2018 | 55 | 0.140 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 155 | 0.140 |
Why?
| | Repressor Proteins | 2 | 2018 | 427 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 327 | 0.140 |
Why?
| | Translocation, Genetic | 1 | 2018 | 105 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2018 | 86 | 0.140 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 455 | 0.140 |
Why?
| | Humans | 13 | 2025 | 136768 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 170 | 0.130 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 3405 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 647 | 0.110 |
Why?
| | Child, Preschool | 4 | 2020 | 11000 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 614 | 0.100 |
Why?
| | Infant | 3 | 2020 | 9398 | 0.090 |
Why?
| | Mutation | 1 | 2023 | 3946 | 0.090 |
Why?
| | Mice | 2 | 2024 | 17757 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1396 | 0.060 |
Why?
| | Prevalence | 2 | 2023 | 2711 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 80 | 0.060 |
Why?
| | Animals | 2 | 2024 | 36847 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 4013 | 0.050 |
Why?
| | Male | 5 | 2025 | 67311 | 0.050 |
Why?
| | Ribonuclease III | 1 | 2023 | 40 | 0.050 |
Why?
| | Platinum | 1 | 2023 | 49 | 0.050 |
Why?
| | Thioguanine | 1 | 2022 | 19 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2023 | 76 | 0.050 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2021 | 94 | 0.040 |
Why?
| | Female | 4 | 2025 | 72796 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 672 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2020 | 18 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2020 | 115 | 0.040 |
Why?
| | Tandem Repeat Sequences | 1 | 2018 | 21 | 0.040 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 34 | 0.040 |
Why?
| | Adolescent | 3 | 2025 | 21382 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1772 | 0.040 |
Why?
| | Allografts | 1 | 2018 | 146 | 0.030 |
Why?
| | Tretinoin | 1 | 2018 | 123 | 0.030 |
Why?
| | Whole Genome Sequencing | 1 | 2018 | 153 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2018 | 316 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 535 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 219 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2792 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2412 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 712 | 0.030 |
Why?
| | Kidney | 1 | 2018 | 1467 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6033 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7572 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 5076 | 0.010 |
Why?
|
|
Shirai's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|